Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase EARLY_PHASE1 1

Status

Completed 14Unknown 6Recruiting 4Terminated 3Active not recruiting 2Suspended 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Pain 2Neoplasms 1Neoplasm Metastasis 1Hematologic Neoplasms 1Emergencies 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Hydromorphone × Clear all
NCT03579446 2025-08-03

Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Terminated
43 enrolled
Other hematologic neoplasm

Neoplasm Metastasis, Hematologic Neoplasms

NCT01812759 2021-06-29

Fentanyl for Breakthrough Pain in the Emergency Department

M.D. Anderson Cancer Center

Phase 4 Terminated
3 enrolled 8 charts

Emergencies, Pain

NCT01648699 2013-10-11

Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain

Janssen Pharmaceutica

Phase 4 Terminated
20 enrolled 9 charts

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡